Parkinson’s Disease - Efficacy, Safety, and Tolerability of Pioglitazone
Protocol ID
Not available
Protocol Description
The FS-ZONE trial will study the effect of pioglitazone (Actos®) on the progression (change over time) of PD over 44 weeks. The study will evaluate whether pioglitazone (Actos®) is safe and well tolerated. We will study two doses of pioglitazone: 15 and 45 milligrams taken once daily and there will be at least six (6) in-person visits and one (1) telephone call over 48weeks (1 year).
Eligibility Criteria
• Men and women between the ages 30 - 80
• Persons diagnosed with idiopathic Parkinson’s disease for less than 5 years
• Persons taking a stable dose of dopamine agonist
• Persons taking rasagiline (Azilect) 1 mg/day or selegiline (Deprenyl, Eldepryl) 10 mg/day for at least 8 weeks but no more than 8 months
Primary Investigator(s)
- Andrew Feigin, MD